Clinical Trials
27 trialsNCT03784014 2026-04-29
MULTISARC
Institut National de la Santé Et de la Recherche Médicale, France
Phase 3 Completed
NCT00680901 2025-08-07
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
Novartis
Phase 3 Completed
NCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting
NCT01300962 2023-12-04
Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT00807859 2022-11-08
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Amgen
Phase 1 Completed
NCT01499160 2022-02-11
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
University of Maryland, Baltimore
Phase 2 Terminated
NCT02650752 2021-01-26
Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01471847 2020-12-09
A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab
Novartis
Phase 1 Completed
NCT01190241 2020-11-20
TSAP
Amsterdam UMC, location VUmc
Phase NA Terminated
NCT00367471 2020-09-09
Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.
Novartis
Phase 1 Completed
NCT01118975 2019-11-13
GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
University of Maryland, Baltimore
Phase 1/2 Terminated
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT00777101 2018-08-09
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
Puma Biotechnology, Inc.
Phase 2 Completed
NCT00073008 2017-02-28
A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer
GlaxoSmithKline
Phase 2 Terminated
NCT01283789 2017-02-08
Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer
University of Kansas Medical Center
Phase 2 Unknown
NCT02238509 2016-06-15
Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies
Consorzio Oncotech
Phase 2 Unknown
NCT00347919 2016-02-25
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00526669 2016-01-29
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
GlaxoSmithKline
Phase 2 Completed
NCT01985893 2016-01-14
THOR
Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.
Phase 2 Withdrawn
NCT01087983 2015-11-11
Lapatinib With Sirolimus or Metformin
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01427322 2015-07-08
Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease
Virginia Commonwealth University
Phase EARLY_PHASE1 Terminated
NCT00044343 2014-07-10
GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin
GlaxoSmithKline
Phase 2 Completed
NCT00544804 2014-07-02
Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2
University of California, San Francisco
Phase 1 Completed
NCT00967031 2013-01-18
Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases
UNICANCER
Phase 2 Completed
NCT00657137 2012-03-15
APRiCOT-B
Tragara Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00078572 2010-12-13
Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer
GlaxoSmithKline
Phase 3 Completed
NCT00239200 2008-07-30
Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus
University of Michigan Rogel Cancer Center
Phase 2 Terminated